NXGL NEXGEL, INC.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1468929 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.5%
TTM net income YoY-130.7%
TTM EPS YoY-45.3%
Revenue 3-yr CAGR51.6%
Net income 3-yr CAGR—
Margins
Gross margin33.4%
Operating margin-58.6%
Net margin-54.0%
FCF margin—
EBITDA margin-40.4%
Returns
ROE-142.7%
ROA-37.4%
ROIC (approx.)-153.8%
Asset turnover0.69x
Leverage & solvency
Liabilities / assets80.5%
Debt / equity0.00x
Current ratio0.46x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.53x
Accruals ratio-17.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.18M | $3.69M | $2.65M | $2.80M | $2.93M | $2.88M | $2.81M | $3.04M |
| Cost of revenue | $2.05M | $2.58M | $1.59M | $1.98M | $1.69M | $1.63M | $1.62M | $2.26M |
| Gross profit | $1.12M | $1.11M | $1.06M | $819,000 | $1.24M | $1.26M | $1.19M | $779,000 |
| R&D expense | $0 | $20,000 | — | -$6,000 | $7,000 | $0 | $1,000 | $0 |
| SG&A expense | $3.66M | $3.59M | $2.02M | $2.04M | $1.96M | $1.89M | $1.96M | $1.62M |
| Operating income | -$2.54M | -$2.50M | -$958,000 | -$1.21M | -$725,000 | -$636,000 | -$777,000 | -$841,000 |
| Interest expense | — | — | — | — | — | — | — | $14,000 |
| Pretax income | -$1.09M | -$3.61M | -$871,000 | -$928,000 | -$647,000 | -$640,000 | -$678,000 | -$824,000 |
| Net income | -$1.11M | -$3.63M | -$927,000 | -$970,000 | -$653,000 | -$665,000 | -$712,000 | -$850,000 |
| EBITDA | -$1.33M | -$1.68M | -$859,000 | -$1.10M | -$612,000 | -$525,000 | -$663,000 | -$733,000 |
| EPS (basic) | -2.28 | -0.40 | -0.11 | — | -1.64 | -0.09 | -0.09 | — |
| EPS (diluted) | -2.28 | -0.40 | -0.11 | — | -1.64 | -0.09 | -0.09 | — |
| Weighted avg. shares (diluted) | 487,357 | 9.01M | 8.20M | — | 398,565 | 7.65M | 7.65M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $658,000 | $1.71M | $2.12M | $317,000 | $1.86M | $725,000 | $1.19M | $1.81M |
| Receivables | $804,000 | $1.08M | $662,000 | $673,000 | $839,000 | $753,000 | $926,000 | $933,000 |
| Inventory | $2.75M | $2.30M | $2.26M | $2.11M | $2.02M | $1.82M | $1.85M | $1.75M |
| Current assets | $4.94M | $6.17M | $5.64M | $4.34M | $5.60M | $4.16M | $4.74M | $5.11M |
| PP&E, net | $1.88M | $1.91M | $1.89M | $1.96M | $2.00M | $2.07M | $2.13M | $2.21M |
| Goodwill | $1.13M | $1.13M | $1.13M | $1.13M | $1.13M | $1.13M | $1.13M | $1.13M |
| Intangibles | $12.34M | $13.49M | $655,000 | $681,000 | $712,000 | $744,000 | $681,000 | $807,000 |
| Total assets | $23.90M | $26.45M | $11.60M | $10.46M | $11.62M | $9.71M | $10.44M | $10.98M |
| Current liabilities | $10.63M | $14.44M | $3.31M | $2.96M | $3.31M | $2.40M | $2.52M | $2.47M |
| Long-term debt | — | — | $563,000 | $588,000 | $614,000 | $638,000 | $662,000 | $685,000 |
| Total debt | — | — | $563,000 | $588,000 | $614,000 | $638,000 | $662,000 | $685,000 |
| Total liabilities | $19.23M | $20.98M | $7.12M | $5.57M | $6.04M | $4.66M | $4.87M | $4.90M |
| Shareholders' equity | $4.13M | $4.95M | $3.99M | $4.46M | $5.19M | $4.67M | $5.21M | $5.75M |
| Net debt | — | — | -$1.56M | $271,000 | -$1.24M | -$87,000 | -$530,000 | -$1.12M |
| Shares outstanding | 487,383 | 9.70M | 8.48M | 407,157 | 8.14M | 7.65M | 7.65M | 7.64M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.13M | -$2.20M | -$504,000 | $281,000 | -$785,000 | -$407,000 | -$400,000 | -$859,000 |
| Capital expenditure | — | — | $9,000 | $40,000 | $8,000 | — | — | $69,000 |
| Free cash flow | — | — | -$513,000 | $241,000 | -$793,000 | — | — | -$928,000 |
| Investing cash flow | -$33,000 | -$6.58M | -$9,000 | -$40,000 | -$8,000 | — | — | -$63,000 |
| Financing cash flow | $116,000 | $8.36M | $1.58M | -$1.04M | $1.93M | -$40,000 | -$215,000 | $1.67M |
| Depreciation & amortization | $1.21M | $827,000 | $99,000 | $112,000 | $113,000 | $111,000 | $114,000 | $108,000 |
| Stock-based compensation | $15,000 | $119,000 | $143,000 | $156,000 | $205,000 | $127,000 | $166,000 | $96,000 |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.